Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Futu Holdings Ltd (FUTU) vs Medtronic PLC (MDT) Price & Performance

Futu Holdings LtdTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Futu Holdings Ltd vs Medtronic PLC — how do they compare? Futu Holdings Ltd trades at $105.55 (market cap $15.24B), while Medtronic PLC trades at $90.79 (market cap $114.45B). The key difference: Medtronic PLC is far larger — about 7.5× Futu Holdings Ltd's market cap, and Medtronic PLC pays the higher dividend (3.22%). Which is the better fit depends on your goals.

FUTUMDT
Market Cap
$15.24B$114.45B
Sector
FinancialsHealth
52-Week High
$199.04$105.35
52-Week Low
$89.76$73.75
Enterprise Value
$15.09B$133.19B
Dividend Yield
2.39%3.22%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Futu Holdings Ltd

Futu Holdings Limited (FUTU) trades at $109.02, up 4.31% today, with a bullish technical signal from moving averages and strong support at $106. The company reported robust 2025 revenue of $22.85 billion and net income of $11.34 billion, with a high net margin of 49.62%. Valuation ratios appear reasonable, with a P/E of 12.07 and P/S of 5.05. However, recent earnings misses in Q1 2026 and a securities class action lawsuit deadline on August 25, 2026, introduce near-term uncertainty.

The outlook for FUTU is mixed: strong profitability and analyst buy ratings (58% consensus) support upside, but legal risks and earnings volatility pose challenges. Investors should weigh solid fundamentals against regulatory and litigation headwinds, with technical levels suggesting $111 as immediate resistance.

Medtronic PLC

Medtronic (MDT) trades at $87.16, up 1.44% today, with a bullish technical signal and consistent earnings beats. The company reported Q1 2026 EPS of $1.55, exceeding expectations, and maintains solid fundamentals with a 13.2% net income margin and $33.54B in revenue for 2025. Recent news highlights growth in cardiac ablation and the Hugo robotic platform, with management guiding for 11.75% organic revenue growth in Q1 2027.

The outlook is positive, supported by analyst consensus of a $98.75 price target and 60% buy ratings. Key opportunities include dividend stability and innovation in medical technology, while risks involve rising debt levels and competitive pressures. The stock's current valuation at a P/E of 23.37 offers moderate upside if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Futu Holdings Ltd

Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.

Read more on FUTU

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT